Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus PT from Analysts

Key Points

• Vigil Neuroscience, Inc. has received an average consensus rating of "Hold" from ten brokerages, reflecting a significant downgrade from previous ratings.
• The company's stock currently has an average 1-year price target of $10.80, while recently revised price objectives have lowered as much as to $8.00.
• Vigil Neuroscience reported a quarterly loss with earnings per share at ($0.56), missing analysts' estimates, and is forecasted to post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) has received a consensus recommendation of "Hold" from the ten ratings firms that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a hold rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.80.

VIGL has been the topic of several research analyst reports. HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and cut their target price for the stock from $14.00 to $8.00 in a research report on Tuesday, May 27th. Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and cut their target price for the stock from $11.00 to $8.00 in a research report on Wednesday, May 28th. William Blair lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Finally, Citizens Jmp downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd.

Vigil Neuroscience Price Performance

VIGL stock remained flat at $8.05 during mid-day trading on Wednesday. The company has a market capitalization of $383.90 million, a P/E ratio of -3.93 and a beta of 3.33. The business has a fifty day simple moving average of $7.99 and a 200 day simple moving average of $4.46. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $8.10.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. Analysts anticipate that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC grew its stake in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Vigil Neuroscience in the second quarter worth $89,000. Northern Trust Corp raised its holdings in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after acquiring an additional 14,572 shares during the last quarter. Barclays PLC raised its holdings in shares of Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Vigil Neuroscience by 103.1% in the second quarter. SG Americas Securities LLC now owns 43,508 shares of the company's stock valued at $346,000 after purchasing an additional 22,091 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.